CN103782171B - 用于检测流体样品中淀粉状蛋白β寡聚体的方法及其用途 - Google Patents

用于检测流体样品中淀粉状蛋白β寡聚体的方法及其用途 Download PDF

Info

Publication number
CN103782171B
CN103782171B CN201280044598.3A CN201280044598A CN103782171B CN 103782171 B CN103782171 B CN 103782171B CN 201280044598 A CN201280044598 A CN 201280044598A CN 103782171 B CN103782171 B CN 103782171B
Authority
CN
China
Prior art keywords
antibody
oligomers
ndpoi
oligomer
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280044598.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103782171A (zh
Inventor
M.萨瓦奇
P.舒鲁埃
A.沃尔夫
A.麦坎贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN103782171A publication Critical patent/CN103782171A/zh
Application granted granted Critical
Publication of CN103782171B publication Critical patent/CN103782171B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
CN201280044598.3A 2011-07-13 2012-07-09 用于检测流体样品中淀粉状蛋白β寡聚体的方法及其用途 Active CN103782171B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161507332P 2011-07-13 2011-07-13
US61/507332 2011-07-13
PCT/US2012/045886 WO2013009667A1 (en) 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof

Publications (2)

Publication Number Publication Date
CN103782171A CN103782171A (zh) 2014-05-07
CN103782171B true CN103782171B (zh) 2016-12-14

Family

ID=47506433

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280044598.3A Active CN103782171B (zh) 2011-07-13 2012-07-09 用于检测流体样品中淀粉状蛋白β寡聚体的方法及其用途

Country Status (13)

Country Link
US (2) US20130052670A1 (https=)
EP (2) EP2732289B1 (https=)
JP (1) JP2014521089A (https=)
KR (1) KR20140072019A (https=)
CN (1) CN103782171B (https=)
AU (1) AU2012282825B2 (https=)
BR (1) BR112014000671A2 (https=)
CA (1) CA2840976A1 (https=)
DK (1) DK2732289T3 (https=)
ES (1) ES2666840T3 (https=)
MX (1) MX2014000480A (https=)
RU (1) RU2014105172A (https=)
WO (2) WO2013009667A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2699827T3 (es) 2009-06-17 2019-02-13 Biogen Ma Inc Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
IL245703B (en) * 2013-11-20 2022-07-01 Univ Iowa Res Found Methods and compositions for treating amyloid deposits
EP3797780B1 (en) 2014-04-17 2022-09-14 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing in a subject
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
EP3341725B1 (en) * 2015-08-25 2021-08-18 Prothena Biosciences Limited Methods for detecting phosphorylated alpha-synuclein
EP3415912B1 (en) 2016-02-08 2023-03-29 Sysmex Corporation Analyte detection method and reagent kit for detecting analyte
US11198867B2 (en) 2016-06-16 2021-12-14 Ionis Pharmaceuticals, Inc. Combinations for the modulation of SMN expression
CN114026109A (zh) * 2019-07-05 2022-02-08 株式会社岛津制作所 β淀粉样蛋白的单克隆抗体、和使用该抗体的β淀粉样蛋白相关肽的测定方法
CN120505310A (zh) 2020-02-28 2025-08-19 Ionis制药公司 用于调节smn2的化合物和方法
WO2022270901A1 (ko) * 2021-06-25 2022-12-29 장재원 동적 형광 또는 x-선의 표준편차와 자기상관을 활용한 조기 진단 시스템
US20240358805A1 (en) * 2021-08-30 2024-10-31 The Brigham And Women's Hospital, Inc. Methods and materials to treat neurodegenerative disease
WO2024026413A2 (en) * 2022-07-27 2024-02-01 Durin Technologies, Inc. Early detection and monitoring of neurodegenerative diseases using a multi-disease diagnostic platform
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665024A (en) 1984-10-01 1987-05-12 Becton, Dickinson And Company Fluorescent gram stain
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6082205A (en) 1998-02-06 2000-07-04 Ohio State University System and device for determining particle characteristics
DE60043165D1 (de) 1999-08-04 2009-11-26 Univ Southern California Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
JP2008502880A (ja) * 2004-04-02 2008-01-31 メルク　エンド　カムパニー　インコーポレーテッド アミロイド前駆体タンパク質又はβアミロイド断片に結合する物質を検出する方法及び結合化合物
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
US7811563B2 (en) * 2004-10-25 2010-10-12 Northwestern University Anti-addl antibodies and uses thereof
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
CN101291692A (zh) * 2005-10-21 2008-10-22 默克制药公司 抗addl单克隆抗体及其应用
US20090181359A1 (en) * 2007-10-25 2009-07-16 Lou Sheng C Method of performing ultra-sensitive immunoassays
CA2779565A1 (en) * 2009-11-24 2011-06-03 Probiodrug Ag Novel diagnostic method for the diagnosis of alzheimer's disease or mild cognitive impairment
WO2011151076A2 (en) * 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
EP2593475B1 (en) * 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂

Also Published As

Publication number Publication date
EP2732286A1 (en) 2014-05-21
WO2013009703A3 (en) 2013-03-21
WO2013009703A2 (en) 2013-01-17
EP2732286A4 (en) 2015-02-25
AU2012282825B2 (en) 2016-05-26
ES2666840T3 (es) 2018-05-08
KR20140072019A (ko) 2014-06-12
EP2732289A2 (en) 2014-05-21
AU2012282825A1 (en) 2014-01-16
CA2840976A1 (en) 2013-01-17
JP2014521089A (ja) 2014-08-25
DK2732289T3 (en) 2018-05-22
RU2014105172A (ru) 2015-08-20
BR112014000671A2 (pt) 2017-02-14
US20130052670A1 (en) 2013-02-28
US20140120037A1 (en) 2014-05-01
MX2014000480A (es) 2014-06-23
WO2013009667A1 (en) 2013-01-17
CN103782171A (zh) 2014-05-07
WO2013009703A8 (en) 2014-01-23
EP2732289B1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
CN103782171B (zh) 用于检测流体样品中淀粉状蛋白β寡聚体的方法及其用途
JP6168364B2 (ja) リン酸化タウ凝集体に対する抗体
EP2828660B1 (en) A method and a kit for the detection of anti-beta amyloid antibodies
CN102713633B (zh) 用于β-淀粉样肽的改进检测的方法和试剂
JP2010535328A (ja) 高感度イムノアッセイおよび生物学的な目的ペプチドおよびタンパク質の測定用キット
US20250020669A1 (en) Methods for detecting neurofilament light chain in plasma and cerebrospinal fluid
US9310383B2 (en) Antibodies, kit and method for detecting amyloid beta oligomers
Tian et al. Isolation and characterization of antibody fragments selective for toxic oligomeric tau
WO2020069621A1 (en) Novel biomarker for alzheimer's disease in human
WO2015004163A1 (en) Anti-tau monoclonal antibodies
US20220365102A1 (en) Tau protein detection method using blood sample as test specimen
JP2018501482A (ja) ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
CN117178189A (zh) 用于检测血浆和脑脊液中的神经丝轻链的方法
WO2026005695A1 (en) Detection of oligomeric tau and soluble tau aggregates
WO2025260029A1 (en) Method for quantifying amyloid beta protofibril
CN121773336A (zh) P-tau免疫测定
TW201321409A (zh) 醫藥組合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20230714

Address after: new jersey

Patentee after: MERCK SHARP & DOHME B.V.

Address before: new jersey

Patentee before: MERCK SHARP & DOHME Corp.

TR01 Transfer of patent right